News

ERDERA - 2025 Call on pre-clinical therapy studies for rare diseases open

Published on | 2 months ago

Programmes Health

The European Partnership on Rare Diseases (ERDERA) has opened its first Joint Transnational Call for Proposals on 'Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation'. The timeline of the call is as follows:

  • Pre-proposal Submission Deadline: 13 February 2025
  • Full Proposal Invitations: Early May 2025
  • Funding Decisions: December 2025


Research Foundation Flanders (FWO) participates in this call. More information on available funding for researchers based in Flanders and on who can apply & how is specified in the call documents. Questions? Please contact europe@fwo.be .

Projects should address at least two of the following:

  • Development of novel therapies in a pre-clinical setting.
  • Creation and validation of predictive and pharmacodynamic biomarkers.
  • Replication of pre-clinical findings to enhance reliability.
  • Pre-clinical proof-of-concept studies for therapy readiness.

Please note, certain approaches, including ATMP therapies and clinical trials, are excluded from this call. Detailed eligibility criteria are outlined in the Call Guidelines.

More information is available on the ERDERA website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1530 articles available search in articles 

Testimonial

image of Lorcenis - Long Lasting Reinforced Concrete for Energy Infrastructures under Severe Operating Conditions

Lorcenis - Long Lasting Reinforced Concrete for Energy Infrastructures under Severe Operating Conditions

ChemStream is an innovative chemical R&D company, specialized in translating material problems in sustainable formulations with focus on nano-dispersions, functional coatings and inkjet inks. Within LORCENIS they will develop super absorbing polymers (SAPs) to be mixed within the concrete matrices for improving the active internal curing, self-healing and self-sealing properties of the concrete. Grindig SAPs.

ChemStream bvba and Ghent University are involved in Horizon 2020-project for developing long lasting reinforced concrete for energy infrastructures.